ArticleFrontiers in immunology2023
Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 22 citations in OpenAlex.
- IL-17 Receptor inhibition with brodalumab limits experimental periodontitis.Journal of translational medicine · 2026Article
- Restorative potential of laser-synthesized silver nanoparticles withBeilstein journal of nanotechnology · 2026Article
- Association of Disease-Modifying Antirheumatic Drugs (DMARDs) with Cardiovascular Diseases: Evidence from a Drug Target Mendelian Randomization Study.Global heart · 2026Article
- Molecular cytokine-dependent mechanisms of periodontitis pathogenesis and the potential for pharmacological IL-1 modulation in disease treatment.Frontiers in dental medicine · 2026Review
- Proteome-Guided Drug Target Discovery for Periodontitis.Journal of clinical periodontology · 2026Article
- Effectiveness of local Tocilizumab administration in mitigating alveolar bone loss and inflammation in experimental periodontitis.Scientific reports · 2025Article
- Association Between Periodontitis and Cancer: A Perspective Review of Mechanisms and Clinical Evidence.Journal of clinical medicine · 2025Article
- Mechanism of Salvia miltiorrhiza in the treatment of periodontitis: integrative analyses via network pharmacology, molecular dynamics, and cellular assays.BMC complementary medicine and therapies · 2025Article
- Transcriptional regulation of human follicular dendritic cell-secreted protein gene by interleukin-6.Odontology · 2025Article
- Evaluating the Efficacy of Resveratrol-Containing Mouthwash as an Adjunct Treatment for Periodontitis: A Randomized Clinical Trial.European journal of dentistry · 2025Article
- Review
- Review of the mechanism of infection induced cerebral small vessel disease.Frontiers in immunology · 2025Review
- Hallmarks of Periodontitis.Current medicinal chemistry · 2025Review
- Clinical Outcomes and Cytokine Profile of Standard and Short Implant-supported Prostheses in Diabetics Treated for Periodontal Disease: A 5-year Study.Oral health & preventive dentistry · 2024Article
- Genetically Supported Drug Targets and Dental Traits: A Mendelian Randomization Study.Journal of dental research · 2024Article
- Article
- The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.Frontiers in immunology · 2024Review
- Therapeutic potential of single-nucleotide polymorphism-mediated IL6R inhibitors in ankylosing spondylitis treatment.Frontiers in medicine · 2024Article
- Diabetes mellitus and prostate cancer risk: A mendelian randomization analysis.World journal of diabetes · 2023Article
- aMMP-8 and MMP-9: Potential Biomarkers for periodontitis Progression in Patients Receiving Radiotherapy for Head and Neck Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Interleukin 6 (IL-6) is considered to play a role in the dysbiotic host response in the development of periodontitis. While the inhibition of the IL-6 receptor using monoclonal antibodies is a well-established therapy for some diseases, so far, its potential benefit in patients with periodontitis has not been examined. We tested the association of genetically proxied downregulation of IL-6 signaling with periodontitis to explore whether downregulation of IL-6 signaling could represent a viable treatment target for periodontitis. Materials and methods: As proxies for IL-6 signaling downregulation, we selected 52 genetic variants in close vicinity of the gene encoding IL-6 receptor that were associated with lower circulating C-reactive protein (CRP) levels in a genome-wide association study (GWAS) of 575 531 participants of European ancestry from the UK Biobank and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Associations with periodontitis were tested with inverse-variance weighted Mendelian randomization in a study of 17 353 cases and 28 210 controls of European descent in the Gene-Lifestyle Interactions in Dental Endpoints (GLIDE) consortium. In addition, the effect of CRP reduction independent of the IL-6 pathway was assessed. Results: Genetically proxied downregulation of IL-6 signaling was associated with lower odds of periodontitis (odds ratio (OR) = 0.81 per 1-unit decrement in log-CRP levels; 95% confidence interval (CI): [0.66;0.99]; P = 0.0497). Genetically proxied reduction of CRP independent of the IL-6 pathway had a similar effect (OR = 0.81; 95% CI: [0.68; 0.98]; P = 0.0296). Conclusion: In conclusion, genetically proxied downregulation of IL-6 signaling was associated with lower odds of periodontitis and CRP might be a causal target for the effect of IL-6 on the risk of periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.